Skip to content

Home
IOncology
Infectious Desease Frontier
IHepatology
Hematology Frontier
Conference topics
Experts Interviews
Informations
Live Broadcasting
Logout

Connecting Medical Expertise through Media

Search for:

Home
IOncology
Infectious Disease Frontier
International Hepatology
Hematology Frontier
Conference topics
Experts’ Interviews
Informations

Home
IOncology
Infectious Disease Frontier
International Hepatology
Hematology Frontier
Conference topics
Experts’ Interviews
Informations

Search for:

Acute Lymphoblastic Leukemia

Home » Acute Lymphoblastic Leukemia

2024 CASH | Professor XiaoFan Zhu : Immunotherapy Strategy Brings Greater Benefits to Children with ALL

2024 CASH | Professor XiaoFan Zhu : Immunotherapy Strategy Brings Greater Benefits to Children with ALL

Posted by

By Yin, Jiale 2024.01.26

Children with Acute Lymphoblastic Leukemia (ALL) have a five-year overall survival (OS) rate exceeding 90%, but about 20% still experience disease relapse. Treating these relapsed or refractory ALL cases is…

The Role of PD-1 Signaling in T-Cell Acute Lymphoblastic Leukemia: A Revolutionary Breakthrough

The Role of PD-1 Signaling in T-Cell Acute Lymphoblastic Leukemia: A Revolutionary Breakthrough

Posted by

By Yin, Jiale 2024.01.22

In January 2023, a study led by Professor Meng Zhao from Zhongshan School of Medicine was published in the prestigious international academic journal ——Nature Cell Biology (IF=21.3). The title of the study is…

Recent Posts

Breaking the Adjuvant Monotherapy Standard: LITESPARK-022 Study Shows 28% Reduction in Recurrence Risk for High-Risk ccRCC
Redefining First-Line nccRCC Treatment: Fruquintinib plus Serplulimab Combination Achieves 97.2% Disease Control Rate
Transcending HER2 Expression Boundaries: RC48 Achieves Breakthrough Benefits in Both HER2-Positive and HER2-Low Advanced Urothelial Carcinoma
Overcoming “Low-Shedding” Barriers: Prof. Taigo Kato Highlights the Value of WGS-Based ctDNA Monitoring in Postoperative RCC
KEYNOTE-905 Update: EV plus Pembrolizumab Achieves 57% pCR and Significantly Extends DFS in Muscle-Invasive Bladder Cancer

Recent Comments

Archives

Categories

Artificial intelligence
Hematology Frontier
Infectious Disease Frontier
International Hepatology
IOncology
Live broadcasting
Uncategorized
UroStream

LinkedIn
Twitter
Mail

Related Media:

Copyright 2026 — MediaMedic. All rights reserved. Blogun WordPress Theme
Paris, France